Evidence map›Paper›PMID 42293394›Full record

ArticleMaterials today. Bio2026

Dual-responsive peptide nanoplatform for improved lung cancer therapy via the synergistic suppression of autophagy and drug efflux.

Ziru Liu, Hongjie Li, Wei Gao, Wenhao Wang, Chuntao Li, Haiqin Huang, Jin Liu, Junjie Li, Huiying Jia, Cheng Ma and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ziru LiuSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Hongjie LiSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Wei GaoAffiliated Hospital of Shandong Second Medical University, School of Medical Sciences, Shandong Second Medical University, Weifang, 261053, China.
Wenhao WangDepartment of Oncology, Affiliated Hospital of Shandong Second Medical University, Weifang, 261053, China.
Chuntao LiSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Haiqin HuangSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Jin LiuAffiliated Hospital of Shandong Second Medical University, School of Medical Sciences, Shandong Second Medical University, Weifang, 261053, China.
Junjie LiSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Huiying JiaAffiliated Hospital of Shandong Second Medical University, School of Medical Sciences, Shandong Second Medical University, Weifang, 261053, China.
Cheng MaSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Yuanxin SongAffiliated Hospital of Shandong Second Medical University, School of Medical Sciences, Shandong Second Medical University, Weifang, 261053, China.
Changgang SunSchool of Traditional Chinese Medicine, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Tongyi SunSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.
Jingkun BaiSchool of Bioscience and Technology, Affiliated Hospital of Shandong Second Medical University, Shandong Second Medical University, Weifang, 261053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of traditional chemotherapy in the treatment of non-small cell lung cancer (NSCLC) is often compromised by poor targeting, barriers posed by the tumor microenvironment, and active drug efflux. Furthermore, tumor cells significantly reduce their sensitivity to chemotherapeutic drugs by activating protective autophagy pathways, which is a key mechanism contributing to treatment failure. We designed and synthesized a smart responsive amphiphilic peptide, Pep1, featuring targeted modification with the Arg-Gly-Asp (RGD) peptide and triphenylphosphonium (TPP). Pep1 efficiently coloads paclitaxel (PTX) and hydroxychloroquine (HCQ) (PH/Pep1) and self-assembles into spherical nanoparticles.

Indexed as

Autophagy inhibitionEnzyme-responsivePeptidesSelf-assemblyTargeted therapies

Identifiers

PMID42293394
PMCPMC13253184

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.